These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 12168883)
1. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients. Hu XC; Day W; Jones B; Loo WT; Chow LW Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Samy N; Ragab HM; El Maksoud NA; Shaalan M Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232 [TBL] [Abstract][Full Text] [Related]
3. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients. Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851 [TBL] [Abstract][Full Text] [Related]
4. [Clinical and prognostic significance of preoperative serum CA153, CEA and TPS levels in patients with primary breast cancer]. Chen Y; Zheng YH; Lin YY; Hu MH; Chen YS Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):842-6. PubMed ID: 22335950 [TBL] [Abstract][Full Text] [Related]
5. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA. Willsher PC; Beaver J; Blamey RW; Robertson JF Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057 [TBL] [Abstract][Full Text] [Related]
6. Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis. Ebeling FC; Schmitt UM; Untch M; Nagel D; Fateh-Moghadam A; Stieber P; Seidel D Anticancer Res; 1999; 19(4A):2545-50. PubMed ID: 10470192 [TBL] [Abstract][Full Text] [Related]
7. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247 [TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Lumachi F; Brandes AA; Boccagni P; Polistina F; Favia G; D'Amico DF Anticancer Res; 1999; 19(5C):4485-9. PubMed ID: 10650797 [TBL] [Abstract][Full Text] [Related]
9. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer. Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485 [TBL] [Abstract][Full Text] [Related]
10. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer. Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478 [TBL] [Abstract][Full Text] [Related]
11. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors. Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573 [TBL] [Abstract][Full Text] [Related]
12. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144 [TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Molina R; Filella X; Zanon G; Pahisa J; Alicarte J; Munoz M; Farrus B; Ballesta AM Anticancer Res; 2003; 23(2A):1043-50. PubMed ID: 12820345 [TBL] [Abstract][Full Text] [Related]
14. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Schuurman JJ; Bong SB; Einarsson R Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538 [TBL] [Abstract][Full Text] [Related]
15. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer]. Zheng H; Luo RC Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113 [TBL] [Abstract][Full Text] [Related]
16. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Lai IR; Lee WJ; Huang MT; Lin HH Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226 [TBL] [Abstract][Full Text] [Related]
17. Serum tumor markers in colorectal cancer staging, grading, and follow-up. Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835 [TBL] [Abstract][Full Text] [Related]
18. [CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma]. Maffei S; Rudoni M; Antonini G; Sacchetti G; Krengli M Minerva Med; 1990 Nov; 81(11):759-63. PubMed ID: 2255409 [TBL] [Abstract][Full Text] [Related]
19. Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer. Lumachi F; Basso SM; Bonamini M; Marzano B; Milan E; Waclaw BU; Chiara GB Anticancer Res; 2010 Jun; 30(6):2331-4. PubMed ID: 20651388 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]